Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

Trial Details

NCT ID

NCT03340506

Phase

PHASE4

Sponsor

Novartis Pharmaceuticals

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

dabrafenib
trametinib

Locations (sample)

Scottsdale, Arizona, United States|33.50921,-111.89903
Scottsdale, Arizona, United States|33.50921,-111.89903
Bethesda, Maryland, United States|38.98067,-77.10026
Columbus, Ohio, United States|39.96118,-82.99879
Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study whic…
In the opinion of the Investigator would benefit from continued treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →